In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...

GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

GSK) is entering the deal-making conversation with a planned acquisition of IDRx, a Plymouth-based biotech working on precision treatments for gastrointestinal stromal tumours (GIST) The British ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B upfront, with potential for an additional $150M ...

PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times reported ...